Hjem › Kreft (alle typer) › Texas › Irving
Kliniske studier for Kreft (alle typer) i Irving, TX
15 studier for Kreft (alle typer) søker deltakere på steder i og rundt Irving (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
REC-7735 in Participants With Solid Tumors
RekruttererFase 1/2
- NEXT Oncology - Dallas, Irving
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
RekruttererFase 1
- NEXT Dallas, Irving
Registry Study for Radiation Therapy Outcomes
RekruttererObservasjonsstudie
- Texas Center for Proton Therapy, Irving
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
RekruttererFase 3
- US Oncology Research Investigational Products Center, Irving
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekruttererFase 1/2
- NEXT Dallas, Irving
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
RekruttererFase 1
- NEXT Oncology ( Site 0051), Irving
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
RekruttererFase 1/2
- NEXT Oncology ( Site 1012), Irving
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RekruttererFase 1/2
- NEXT Oncology Dallas, Irving
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
RekruttererFase 1
- NEXT Oncology Dallas, Irving
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
RekruttererFase 1
- NEXT Dallas, Irving
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
RekruttererFase 1
- NEXT Dallas, Irving
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RekruttererFase 1/2
- NEXT Oncology, Irving
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
RekruttererFase 1
- NEXT Oncology, Irving
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RekruttererFase 1/2
- NEXT Dallas, Irving
Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up
RekruttererObservasjonsstudie
- Texas Center for Proton Therapy, Irving
Kreft (alle typer)-studier i andre byer
- Houston, TX121 studier
- New York City, NY109 studier
- Boston, MA85 studier
- Los Angeles, CA74 studier
- Nashville, TN65 studier
- Philadelphia, PA59 studier
- Washington, DC58 studier
- Durham, NC58 studier
- Chicago, IL51 studier
- Atlanta, GA49 studier
- Seattle, WA49 studier
- Arlington, VA48 studier
Andre studier i Irving
- Ikke-småcellet lungekreft22 studier
- Kolorektal kreft13 studier
- Metastatisk kreft11 studier
- Brystkreft7 studier
- Mavekreft7 studier
- Pankreaskreft7 studier
- Plateepitelcancer i hode og hals6 studier
- Småcellet lungekreft6 studier
- Lungekreft6 studier
- Eggstokkreft5 studier
- Endometriekreft4 studier
- Tripelnegativ brystkreft4 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.